{"slug":"bispecific-io","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣雙特異性抗體與免疫腫瘤公司總表","summary":[{"text":"截至2026年10月22日，本表收錄4家台灣公司的雙特異性抗體、ADC或免疫細胞激素管線。","source_urls":["https://www.obipharma.com/what-we-do/pipeline-overview/","https://www.formosapharma.com/wp-content/uploads/2026/09/20260902-台新藥法人說明會-final-CHN.pdf","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://clinicaltrials.gov/api/v2/studies/NCT05473156","https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf"]},{"text":"所選OBI-201、TSY-310與PD-1-IL-2v仍在臨床前，AP203整體試驗則登錄為第1/2期。","source_urls":["https://www.obipharma.com/what-we-do/pipeline-overview/","https://www.formosapharma.com/wp-content/uploads/2026/09/20260902-台新藥法人說明會-final-CHN.pdf","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://clinicaltrials.gov/api/v2/studies/NCT05473156"]}],"undisclosed":"本表是核對來源後的公司與所選管線名單，並非完整產業清冊。階段依逐列來源日期描述，未公開的品名、適應症與事件日期不填補。"},"en":{"title":"Taiwan Bispecific Antibody and Immuno-Oncology Companies","summary":[{"text":"As of October 22, 2026, this table includes bispecific antibody, ADC or immunocytokine programs at 4 Taiwan companies.","source_urls":["https://www.obipharma.com/what-we-do/pipeline-overview/","https://www.formosapharma.com/wp-content/uploads/2026/09/20260902-台新藥法人說明會-final-CHN.pdf","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://clinicaltrials.gov/api/v2/studies/NCT05473156","https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf"]},{"text":"The selected OBI-201, TSY-310 and PD-1-IL-2v programs remain preclinical, while the overall AP203 study is registered as Phase 1/2.","source_urls":["https://www.obipharma.com/what-we-do/pipeline-overview/","https://www.formosapharma.com/wp-content/uploads/2026/09/20260902-台新藥法人說明會-final-CHN.pdf","https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","https://clinicaltrials.gov/api/v2/studies/NCT05473156"]}],"undisclosed":"This is a source-verified selection rather than an industry census. Stages retain their individual source dates; undisclosed names, indications and event dates are not filled in."}},"companies":[{"company":"浩鼎","company_en":"OBI Pharma","ticker":"4174","product":"OBI-201（TROP2×HER2雙特異性ADC）","product_en":"OBI-201 (TROP2 × HER2 bispecific ADC)","indication":"實體腫瘤","indication_en":"Solid tumors","stage":"臨床前","stage_en":"Preclinical","as_of":"2026-10-22","source":"https://www.obipharma.com/what-we-do/pipeline-overview/","quote":"OBI-201","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"台灣浩鼎生技股份有限公司","catalyst":null,"date_basis":"無日期現行管線頁；所選OBI-201列Preclinical，as_of為查閱日。"},{"company":"台新藥","company_en":"Formosa Pharmaceuticals","ticker":"6838","product":"TSY-310（EGFR×ROR1雙特異性ADC）","product_en":"TSY-310 (EGFR × ROR1 bispecific ADC)","indication":"實體腫瘤","indication_en":"Solid tumors","stage":"臨床前","stage_en":"Preclinical","as_of":"2026-09-02","source":"https://www.formosapharma.com/wp-content/uploads/2026/09/20260902-台新藥法人說明會-final-CHN.pdf","quote":"TSY-310雙靶點奈米抗體ADC","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台新藥股份有限公司","catalyst":null,"source_page":4,"date_basis":"封面2026年9月2日；第4頁TSY-310色條位於臨床前，第6頁明示EGFR與ROR1雙靶點，已視覺核對。"},{"company":"藥華藥","company_en":"PharmaEssentia","ticker":"6446","product":"PD-1-IL-2v（雙特異性免疫細胞激素）","product_en":"PD-1-IL-2v (bispecific immunocytokine)","indication":"實體腫瘤","indication_en":"Solid tumors","stage":"臨床前；IND-enabling","stage_en":"Preclinical; IND-enabling","as_of":"2026-10-22","source":"https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","quote":"IND ENABLING","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"藥華醫藥股份有限公司","catalyst":{"text":"所引公司法說計畫2026年提交PD-1-IL-2v的IND；尚未核實已提交。","text_en":"The cited company presentation plans an IND for PD-1-IL-2v in 2026; submission is not verified.","as_of":"2026-10-22","source":"https://mopsov.twse.com.tw/nas/STR/644620260825E001.pdf","quote":"Planned IND in 2026"},"source_page":28,"date_basis":"所引法說檔封面未標發布日，as_of採查閱日，不從檔名造日期；第28頁PD-1-IL-2v色條位於IND-enabling，未進入一期，已視覺核對。"},{"company":"圓祥生技","company_en":"AP Biosciences","ticker":"6945","product":"AP203（PD-L1×CD137雙特異性抗體）","product_en":"AP203 (PD-L1 × CD137 bispecific antibody)","indication":"局部晚期或轉移性實體腫瘤","indication_en":"Locally advanced or metastatic solid tumors","stage":"第1/2期試驗；登錄為招募中","stage_en":"Phase 1/2 study; registered as recruiting","as_of":"2025-03-26","source":"https://clinicaltrials.gov/api/v2/studies/NCT05473156","quote":"RECRUITING","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"圓祥生技股份有限公司","catalyst":null,"date_basis":"ClinicalTrials.gov最後公開更新2025-03-26；公司現行法說第7頁另列一期進度，整體登錄期別與目前隊列分開描述。","product_source":"https://www.apbioinc.com/Upload/202605/investor_2026051315284608.pdf","product_quote":"AP203","product_as_of":"2026-10-22"}],"scope":{"not_exhaustive":true,"coverage":"Verified selection from the same read-only company-profile and pipeline inputs used in 0b04, because deploy/engine/src/data does not contain the original company profiles. One program selected per company.","stage_basis":"Stages reflect the cited source and its stated date. An undated live page uses the access date; source review does not make an old status a newly reported event.","count_basis":"Company rows, not independent assets or an industry-wide census. Parent-group, therapeutic-vaccine and planned regulatory-pathway roles are identified in each row."}}